

(2) Non-Technical Abstract

Thomas J. Kipps, M.D./Ph.D. and colleagues are conducting a research study to find out how safe it is to administer leukemia cells that have been modified to express a protein called CD40-ligand, and to find out ways to stimulate an immune response against leukemia cells. There will be approximately 15 participants at this site.

This protocol has three major parts. The first part will require removal of leukemia cells from blood by a process called leukapheresis. The second step, isolated malignant cells will be infected with a genetically altered adenovirus (a form of cold virus). The altered adenovirus contains a normal gene that directs the leukemia cells to make CD40-ligand (CD40-L), a molecule that activates the immune system. In the third step, the modified leukemia cells will be given back to by intravenous infusion. This is done to stimulate your immune system to react against the leukemia cells .